DOCSLIB.ORG

Profile Profile Uses and Administration Pharmacokinetics Adverse Effects

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

1754 Disinfectants and Preservatives Glyoxal solutions, it is advisable to incorporatea sequestrant such as atogenic effects is subject to debate.t2 However, it is con­ disodium edetate.2 sidered best to avoid its use during pregnancy. l. Walter G, Gump W. Effect of pH on hexachlorophene. Soap Chern Spec 1. Halling H. Suspected link between exposure to hexachlorophene and 1963; 39: 55-6. malformed infants. Ann NYAcad Sci 1979; 320: 426-3 5. 2. Bell M. Hexachlorophene-based skin cleansers. Specialities 1965; I: 16- 2. Baltzar B, et al. Pregnancy outcome among women working in Swedish 18. hospitals. N Eng! J Med 1979; 300: 627-8. Uses and Administration Pharmacokinetics Hexachlorophene is a chlorinated bisphenol antiseptic with Hexachlorophene is absorbed from the gastrointestinal tract a bacteriostatic action against Gram-positive organisms, but after accidental ingestion, and through intact and denuded Profile much less effective against Gram-negative organisms. It is , skin. Percutaneous absorption may be significant in premature infants and through damaged skin. Hexachlor­ Glyoxal is an aldehyde used for the disinfection of surfaces most active at pH 5 to 6. 1 and of medical and surgical instruments. Hexachlorophene is mainly used in soaps and creams in a ophene crosses the placenta. concentration of 0.23 to 3% and is an ingredient of various i preparations used for skin disorders. After repeated use of P.r....epa.. .ra. t..ons... .. .. .. these preparations for several days there is a marked ProprietaryPreparations (details are given in Volume B) ProprietaryPreparations (details are given in Volume B) diminution of the bacterial flora due to accumulation of hexachlorophene in the skin. This residual effect is rapidiy Single·ingredient Preparations. Gr.: Acnemaskt; Incoliquid; Multi-ingredient Preparations. Ger.: Buraton 10 Ft; Freka-Nolt; , lost after washing with unmedicated soap or alcohol. Indon.: Dermisan; Thai.: Hexa Clean; Venez. : Solu-Hex. Incidin perfekt; Incidur; Lysoformin 3000; Meliseptol; Melsept A preparation containing 3% is used for the disinfection SF; Ultrasol-F; Ita!.: Inddin Spezialt; Indulfant; Melsept SF; Multi-ingredientPreparations. Canad. : pHisoHex; Cz. : Septonex; Melsept Spray; Melsept. of the hands of surgeons and other healthcare personnel. Gr.: Creme Phyllis de Jeunesse; Hemorrocort; Hemorroidal-H; Thorough rinsing is recommended before drying. Hexa­ Rysolone; Hung.: Phlogosol; Indon.: Topicidet; Irl. : Torbetolt; chlorophene has been applied as a 0. 3 3% dusting powder to Port. : Anacal; Spain: Cresophene; Thai.: Cibist; USA: pHiso­ the umbilical cord stump for the control of staphylococcal Hex; Venez. : Permucal. infection in the newborn. However, care is necessary when Pharmacopaeial Preparations using hexachlorophene in neonates (see below). BP 2014: Hexachlorophene Dusting Powder; Hexachlorophene sodium has also been used. USP 36: Hexachlorophene Cleansing Emulsion; Hexachloro­ phene Liquid Soap. Disinfection. Eradication of an outbreak of infection with meticillin-resistant Staphylococcus aureus in a neonatal intensive care unit was achieved by use of hexachloro­ Hexamidine lsetionate(BANM, rtNNMI phene soap for hand washing. Previous infection -control USP 36: (Halazone). A white crystalline powder with a measures including the use of chlorhexidine had failed. 1 characteristic odour of chlorine. Soluble 1 in more than For a discussion of staphylococcal infections and their 1000 of water and of chloroform, I in 140 of alcohol, and 1 treatment, see p. 208.2. in more than 2000 of ether; soluble in glacial acetic acid. It 1. Reboli AC. et al. Epidemic methicillin-gentamicin-resistant Staphylo­ coccus aureus in a neonatal intensive care unit. Am J DisChild 1989; I43: dissolves in solutions of alkali hydroxides and carbonates 34--9. with the formation of a salt. Store in airtight containers. Protect from light. Adverse Effects and Treatment After ingestion of hexachlorophene, anorexia, nausea, Profile vomiting, diarrhoea, abdominal cramps, dehydration, Halazone is a disinfectant with the general properties of shock, and confusion may occur. Convulsions and death chlorine (p. I 7 46.2) in aqueous solution and is used for the may follow. CNS stimulation, convulsions, and death have disinfection of drinking water (p. 1731.3 ). It contains about also occurred after absorption of hexachlorophene from 52% of 'available chlorine' (see p. 1746.3). One tablet burns and damaged skin. There have been reports showing containing 4 mg of halazone, stabilised with sodium that hexachlorophene can be absorbed through the skin of carbonate and sodium chloride, may be sufficient to treat infants in amounts sufficient to produce spongy lesions of NOTE. The name Hexamidinum has been used for primidone about I litre of water in about 30 minutes to 1 hour. The the brain, sometimes fatal. (p. 547. 1). taste of residual chlorine may be removed by adding sodium Photosensitivity and skin sensitisation have occasionally In Bur. (see p. vii). thiosulfate. occurred after repeated use of hexachlorophene. Pharmacopoeias. Treatment of adverse effects is as for Phenol, p. 1764.3. Ph. Eur. 8: (Hexamidine Diisetionate; Hexamidine i Isetionate BP 2014). A white or slightly yellow hygroscopic ..P...rep. ......ar.a...t..ons.... powder. Sparingly soluble in water; slightly soluble in . .. (details are given in Volume B) Effects on therespiratory system. Asthma developed in a ProprietaryPreparations 43-year-old nurse after long-term exposure to hexachloro­ alcohol; practically insoluble in dichloromethane. Store in airtight containers. Single-ingredient Preparations,Gr.: Helporide; Turk.: Haloseptil. phene powder 1 l. Nagy L, Orosz M. Occupational asthma due to hexachlorophene. Thorax PharmacopaeialPreparations 1984; 39: 630-l. Profile USP 36: Halazone Tablets for Solution. Hexamidine isetionate has antibacterial and antifungal Precautions properties and is available in preparations for the local Hexachlorophene should not be applied to mucous treatment of minor infections. membranes, large areas of skin, or to burnt, damaged, or denuded skin and should not be used vaginally, applied Acanthamoeba keratitis. Hexamidine was suggested 1 as a under occlusive dressings, or applied to areas affected by possible alternative to propamidine for the treatment of dermatoses. It should be used with caution on infants, Acanthamoeba keratitis (p. 919.3) due to the poor cysticidal especially premature and low birth-weight neonates. Its use activity, chronic conjunctival infection, and resistance of I 2 is not advised in pregnancy. some Acanthamoeba strains seen with propamidine. Preparations of hexachlorophene are liable to contam­ Cures have been reported with 0.1% hexamidine used 2 2 ination, especially with Gram-negative bacteria. either as monotherapy .3 or with polihexanide. l. Perrine D, et al. Amoebicidal efficiencies of various diamidines against two strains of Acanthamoeba polyphaga. Antimicrob Agents Chemother Breast feeding. The American Academy of Pediatrics1 con­ 1995; 39: 339--42. siders that, while no effects on the infant have been 2. Murdoch D, et al. Acanthamoeba keratitis in New Zealand, including two reported, there is a possibility of contamination of breast cases with in vivo resistance to polyhexamethylene biguanide. Aust N ZJ milk with hexachlorophene used by breast-feeding Ophthalmol l998; 26: 231-6. (Hexachlorophene). A white or pale buff, 3. Seal DV. Acamhamocba keratitis update-incidence, molecular mothers for nipple washing. I7: odourless or almost odourless, crystalline powder. epidemiology and new drugs for treatment. Eye 2003; 893-905. I. American Academy of Pediatrics. The transfer of drugs and other Practically insoluble in water; freely soluble in alcohol; chemicals into human milk. Pediatrics 2001; 108: 776-89. [Retired May Adverse effects. A systemic allergic reaction in a patient very soluble in acetone and in ether. It dissolves in dilute 2010] Correction. ibid.; 1029. Also available at: http:l/aappolicy. after use of a topical antiseptic cream was confirmed, by solutions of alkali hydroxides. Protect from light. aappublications. org/ cgi/ content /full/pediatrics% 3 b l 08/3177 6 (accessed 15/03/06) skin prick tests, to be caused by hexamidine.1 USP 36: (Hexachlorophene). A white or light tan, 1. Mullins RJ. Systemic allergy to topical hexamidine. Med J Aust 2006; crystalline powder which is odourless or has a slight 185: Neonates. Spongi!orm encephalopathy has occurred in 177. phenolic odour. Insoluble in water; freely soluble in alcohol, neonates who were treated topically with hexachloro­ in acetone, and in ether; soluble in chloroform and in dilute phene 1 Neonates with a birth-weight of 1.4kg or less solutions of fixed alkali hydroxides. Store in airtight appeared to be most susceptible, whereas those weighing containers. Protect from light. ProprietaryPreparations (details are given in Volume B) over 2 kg were not considered to be at risk. 1•2 Also most of the reports involved hexachlorophene applied in a con­ Single-ingredient Preparations. Belg.: Desomedine; Hexomedine; Ophtamedine; Fr.: Desomedine; Hexaseptine; Hexomedine; Incompatibility. The activity of hexachlorophene may be centration of 3%. reduced in the presence of blood or other organic material. Ger.: Laryngomedin Nt; Gr. : Ophtamedine; Singapore: Deso­ 1. Anonymous. Hexachlorophene today. Lancet 1982; i: 87-8. medine; Switz. : Dcsomcdine; Venez. : Hcxomcdine. It retains some activity in the presence of soap. 2. Plueckhabn VD, Collins
Recommended publications
  • National Center for Toxicological Research

    National Center for Toxicological Research

    National Center for Toxicological Research Annual Report Research Accomplishments and Plans FY 2015 – FY 2016 Page 0 of 193 Table of Contents Preface – William Slikker, Jr., Ph.D. ................................................................................... 3 NCTR Vision ......................................................................................................................... 7 NCTR Mission ...................................................................................................................... 7 NCTR Strategic Plan ............................................................................................................ 7 NCTR Organizational Structure .......................................................................................... 8 NCTR Location and Facilities .............................................................................................. 9 NCTR Advances Research Through Outreach and Collaboration ................................... 10 NCTR Global Outreach and Training Activities ............................................................... 12 Global Summit on Regulatory Science .................................................................................................12 Training Activities .................................................................................................................................14 NCTR Scientists – Leaders in the Research Community .................................................. 15 Science Advisory Board ...................................................................................................
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE

    )&F1y3x PHARMACEUTICAL APPENDIX to THE

    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
  • NINDS Custom Collection II

    NINDS Custom Collection II

    ACACETIN ACEBUTOLOL HYDROCHLORIDE ACECLIDINE HYDROCHLORIDE ACEMETACIN ACETAMINOPHEN ACETAMINOSALOL ACETANILIDE ACETARSOL ACETAZOLAMIDE ACETOHYDROXAMIC ACID ACETRIAZOIC ACID ACETYL TYROSINE ETHYL ESTER ACETYLCARNITINE ACETYLCHOLINE ACETYLCYSTEINE ACETYLGLUCOSAMINE ACETYLGLUTAMIC ACID ACETYL-L-LEUCINE ACETYLPHENYLALANINE ACETYLSEROTONIN ACETYLTRYPTOPHAN ACEXAMIC ACID ACIVICIN ACLACINOMYCIN A1 ACONITINE ACRIFLAVINIUM HYDROCHLORIDE ACRISORCIN ACTINONIN ACYCLOVIR ADENOSINE PHOSPHATE ADENOSINE ADRENALINE BITARTRATE AESCULIN AJMALINE AKLAVINE HYDROCHLORIDE ALANYL-dl-LEUCINE ALANYL-dl-PHENYLALANINE ALAPROCLATE ALBENDAZOLE ALBUTEROL ALEXIDINE HYDROCHLORIDE ALLANTOIN ALLOPURINOL ALMOTRIPTAN ALOIN ALPRENOLOL ALTRETAMINE ALVERINE CITRATE AMANTADINE HYDROCHLORIDE AMBROXOL HYDROCHLORIDE AMCINONIDE AMIKACIN SULFATE AMILORIDE HYDROCHLORIDE 3-AMINOBENZAMIDE gamma-AMINOBUTYRIC ACID AMINOCAPROIC ACID N- (2-AMINOETHYL)-4-CHLOROBENZAMIDE (RO-16-6491) AMINOGLUTETHIMIDE AMINOHIPPURIC ACID AMINOHYDROXYBUTYRIC ACID AMINOLEVULINIC ACID HYDROCHLORIDE AMINOPHENAZONE 3-AMINOPROPANESULPHONIC ACID AMINOPYRIDINE 9-AMINO-1,2,3,4-TETRAHYDROACRIDINE HYDROCHLORIDE AMINOTHIAZOLE AMIODARONE HYDROCHLORIDE AMIPRILOSE AMITRIPTYLINE HYDROCHLORIDE AMLODIPINE BESYLATE AMODIAQUINE DIHYDROCHLORIDE AMOXEPINE AMOXICILLIN AMPICILLIN SODIUM AMPROLIUM AMRINONE AMYGDALIN ANABASAMINE HYDROCHLORIDE ANABASINE HYDROCHLORIDE ANCITABINE HYDROCHLORIDE ANDROSTERONE SODIUM SULFATE ANIRACETAM ANISINDIONE ANISODAMINE ANISOMYCIN ANTAZOLINE PHOSPHATE ANTHRALIN ANTIMYCIN A (A1 shown) ANTIPYRINE APHYLLIC
  • A Screening-Based Approach to Circumvent Tumor Microenvironment

    A Screening-Based Approach to Circumvent Tumor Microenvironment

    JBXXXX10.1177/1087057113501081Journal of Biomolecular ScreeningSingh et al. 501081research-article2013 Original Research Journal of Biomolecular Screening 2014, Vol 19(1) 158 –167 A Screening-Based Approach to © 2013 Society for Laboratory Automation and Screening DOI: 10.1177/1087057113501081 Circumvent Tumor Microenvironment- jbx.sagepub.com Driven Intrinsic Resistance to BCR-ABL+ Inhibitors in Ph+ Acute Lymphoblastic Leukemia Harpreet Singh1,2, Anang A. Shelat3, Amandeep Singh4, Nidal Boulos1, Richard T. Williams1,2*, and R. Kiplin Guy2,3 Abstract Signaling by the BCR-ABL fusion kinase drives Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph+ ALL) and chronic myelogenous leukemia (CML). Despite their clinical activity in many patients with CML, the BCR-ABL kinase inhibitors (BCR-ABL-KIs) imatinib, dasatinib, and nilotinib provide only transient leukemia reduction in patients with Ph+ ALL. While host-derived growth factors in the leukemia microenvironment have been invoked to explain this drug resistance, their relative contribution remains uncertain. Using genetically defined murine Ph+ ALL cells, we identified interleukin 7 (IL-7) as the dominant host factor that attenuates response to BCR-ABL-KIs. To identify potential combination drugs that could overcome this IL-7–dependent BCR-ABL-KI–resistant phenotype, we screened a small-molecule library including Food and Drug Administration–approved drugs. Among the validated hits, the well-tolerated antimalarial drug dihydroartemisinin (DHA) displayed potent activity in vitro and modest in vivo monotherapy activity against engineered murine BCR-ABL-KI–resistant Ph+ ALL. Strikingly, cotreatment with DHA and dasatinib in vivo strongly reduced primary leukemia burden and improved long-term survival in a murine model that faithfully captures the BCR-ABL-KI–resistant phenotype of human Ph+ ALL.
  • Avant-Propos Le Format De Présentation De Cette Thèse Correspond À Une Recommandation À La Spécialité

    Avant-Propos Le Format De Présentation De Cette Thèse Correspond À Une Recommandation À La Spécialité

    Avant-propos Le format de présentation de cette thèse correspond à une recommandation à la spécialité Maladies infectieuses, à l’intérieur du Master des Sciences de la Vie et de la Santé qui dépend de l’Ecole Doctorale des Sciences de la Vie de Marseille. Le candidat est amené à respecter les règles qui lui sont imposées et qui comportent un format de thèse utilisé dans le Nord de l’Europe et qui permet un meilleur rangement que les thèses traditionnelles. Par ailleurs, la partie introduction et bibliographie est remplacée par une revue envoyée dans un journal afin de permettre une évaluation extérieure de la qualité de la revue et de permettre à l’étudiant de commencer le plus tôt possible une bibliographie sur le domaine de cette thèse. Par ailleurs, la thèse est présentée sur article publié, accepté, ou soumis associé d’un bref commentaire donnant le sens général du travail. Cette forme de présentation a paru plus en adéquation avec les exigences de la compétition internationale et permet de se concentrer sur des travaux qui bénéficieront d’une diffusion internationale. Professeur Didier RAOULT 2 Remerciements J’adresse mes remerciements aux personnes qui ont contribué à la réalisation de ce travail. En premier lieu, au Professeur Didier RALOUT, qui m’a accueillie au sein de l’IHU Méditerranée Infection. Au Professeur Serge MORAND, au Docteur Marie KEMPF et au Professeur Philippe COLSON de m’avoir honorée en acceptant d’être rapporteurs et examinateurs de cette thèse. Je souhaite particulièrement remercier : Le Professeur Jean-Marc ROLAIN, de m’avoir accueillie dans son équipe et m’avoir orientée et soutenue tout au long de ces trois années de thèse.
  • Step-By-Step Guide to Better Laboratory Management Practices

    Step-By-Step Guide to Better Laboratory Management Practices

    Step-by-Step Guide to Better Laboratory Management Practices Prepared by The Washington State Department of Ecology Hazardous Waste and Toxics Reduction Program Publication No. 97- 431 Revised January 2003 Printed on recycled paper For additional copies of this document, contact: Department of Ecology Publications Distribution Center PO Box 47600 Olympia, WA 98504-7600 (360) 407-7472 or 1 (800) 633-7585 or contact your regional office: Department of Ecology’s Regional Offices (425) 649-7000 (509) 575-2490 (509) 329-3400 (360) 407-6300 The Department of Ecology is an equal opportunity agency and does not discriminate on the basis of race, creed, color, disability, age, religion, national origin, sex, marital status, disabled veteran’s status, Vietnam Era veteran’s status or sexual orientation. If you have special accommodation needs, or require this document in an alternate format, contact the Hazardous Waste and Toxics Reduction Program at (360)407-6700 (voice) or 711 or (800) 833-6388 (TTY). Table of Contents Introduction ....................................................................................................................................iii Section 1 Laboratory Hazardous Waste Management ...........................................................1 Designating Dangerous Waste................................................................................................1 Counting Wastes .......................................................................................................................8 Treatment by Generator...........................................................................................................12
  • Bleach) in Health-Care Facilities

    Bleach) in Health-Care Facilities

    CLINICAL MICROBIOLOGY REVIEWS, Oct. 1997, p. 597–610 Vol. 10, No. 4 0893-8512/97/$04.0010 Copyright © 1997, American Society for Microbiology Uses of Inorganic Hypochlorite (Bleach) in Health-Care Facilities WILLIAM A. RUTALA* AND DAVID J. WEBER Division of Infectious Diseases, University of North Carolina School of Medicine, and Department of Hospital Epidemiology, University of North Carolina Hospitals, Chapel Hill, North Carolina 27599-7030 INTRODUCTION .......................................................................................................................................................597 HISTORY.....................................................................................................................................................................597 DEFINITIONS ............................................................................................................................................................598 DISEASE TRANSMISSION IN HEALTH-CARE FACILITIES ..........................................................................598 CHARACTERISTICS OF THE IDEAL DISINFECTANT....................................................................................599 CHLORINE COMPOUNDS WITH ANTIMICROBIAL ACTIVITY ...................................................................599 Available Agents......................................................................................................................................................599 Mechanism of Action..............................................................................................................................................600
  • Chlorhexidine Bathing in a Tertiary Care Neonatal Intensive Care Unit

    Chlorhexidine Bathing in a Tertiary Care Neonatal Intensive Care Unit

    Chlorhexidine Bathing in a Tertiary Care Neonatal Intensive Care Unit: Impact on Central Line–Associated Bloodstream Infections Author(s): Caroline Quach, MD, MSc; Aaron M. Milstone, MD, MHS; Chantal Perpête, RN, LSH, LSHH; Mario Bonenfant, RN; Dorothy L. Moore, MD, PhD; Therese Perreault, MD Source: Infection Control and Hospital Epidemiology, Vol. 35, No. 2 (February 2014), pp. 158- 163 Published by: The University of Chicago Press on behalf of The Society for Healthcare Epidemiology of America Stable URL: http://www.jstor.org/stable/10.1086/674862 . Accessed: 24/01/2014 14:25 Your use of the JSTOR archive indicates your acceptance of the Terms & Conditions of Use, available at . http://www.jstor.org/page/info/about/policies/terms.jsp . JSTOR is a not-for-profit service that helps scholars, researchers, and students discover, use, and build upon a wide range of content in a trusted digital archive. We use information technology and tools to increase productivity and facilitate new forms of scholarship. For more information about JSTOR, please contact [email protected]. The University of Chicago Press and The Society for Healthcare Epidemiology of America are collaborating with JSTOR to digitize, preserve and extend access to Infection Control and Hospital Epidemiology. http://www.jstor.org This content downloaded from 209.172.182.131 on Fri, 24 Jan 2014 14:25:10 PM All use subject to JSTOR Terms and Conditions infection control and hospital epidemiology february 2014, vol. 35, no. 2 original article Chlorhexidine Bathing in a Tertiary Care Neonatal Intensive Care Unit: Impact on Central Line–Associated Bloodstream Infections Caroline Quach, MD, MSc;1,2,3 Aaron M.
  • Chemicals of High Concern List (Sorted Alphabetically), July 2010

    Chemicals of High Concern List (Sorted Alphabetically), July 2010

    Minnesota Department of Health, Chemicals of High Concern list, July 1, 2010 Persistent, Bioaccumulative, Toxic or very CAS Persistent, very HPV (2006 and 3 of 4 Number Chemical Name Health endpoint(s) Bioaccumulative Source(s) Use example(s) or class years) (S)-4-hydroxy-3-(3-oxo-1-phenylbutyl)-2- Maine (EU Reproductive 5543-57-7 benzopyrone Reproduction Toxicant) Sunscreen Maine (CA Prop 65; IARC; EU Carcinogen; NTP 11th ROC; OSPAR Chemicals of High Concern); WA Appen1; 91-94-1 [1,1'-biphenyl]-4,4'-diamine, 3,3'-dichloro-Cancer x Minnesota HRL Dye, curing agent Maine (OSPAR Chemicals of [1,1'-biphenyl]-4,4'-diamine, N,N'-bis(2,4- Concern; Canada PBiT); WA 29398-96-7 dinitrophenyl)-3,3'-dimethoxy- x Appen1 Colorant [1,1'-Biphenyl]-4-ol, 3,4',5-tris(1,1- Maine (Canada PBiT); WA 6257-39-2 dimethylethyl)- x Appen1 [1,1'-Biphenyl]-4-ol, 3,4'-bis(1,1- Maine (Canada PBiT); WA 42479-88-9 dimethylethyl)- x Appen1 Chemical intermediate [1,1'-biphenyl]-4-ol, 3,5-bis(1,1- Maine (OSPAR Chemicals of 2668-47-5 dimethylethyl)- x Concern); WA Appen1 [2,6'-Bibenzothiazole]-7-sulfonic acid, 2'- (4-aminophenyl)-6-methyl-, diazotized, coupled with diazotized 4- aminobenzenesulfonic acid and Maine (Canada PBiT); WA 91696-90-1 resorcinol, sodium salts x Appen1 1(2H)-Quinolineethanol, 6-[(2-chloro-4,6- dinitrophenyl) azo]-3,4-dihydro-2,2,4,7- Maine (Canada PBiT); WA 63133-84-6 tetramethyl- x Appen1 1(2H)-Quinolinepropanamide, 6-(2,2- dicyanoethenyl)-3, 4-dihydro-2,2,4,7- Maine (Canada PBiT); WA 63467-15-2 tetramethyl-N-phenyl- x Appen1 1,1,1,2-Tetrachloro-2,2-bis(4-
  • Guideline for Disinfection and Sterilization in Healthcare Facilities, 2008

    Guideline for Disinfection and Sterilization in Healthcare Facilities, 2008

    Guideline for Disinfection and Sterilization in Healthcare Facilities, 2008 Guideline for Disinfection and Sterilization in Healthcare Facilities, 2008 William A. Rutala, Ph.D., M.P.H.1,2, David J. Weber, M.D., M.P.H.1,2, and the Healthcare Infection Control Practices Advisory Committee (HICPAC)3 1Hospital Epidemiology University of North Carolina Health Care System Chapel Hill, NC 27514 2Division of Infectious Diseases University of North Carolina School of Medicine Chapel Hill, NC 27599-7030 1 Guideline for Disinfection and Sterilization in Healthcare Facilities, 2008 3HICPAC Members Robert A. Weinstein, MD (Chair) Cook County Hospital Chicago, IL Jane D. Siegel, MD (Co-Chair) University of Texas Southwestern Medical Center Dallas, TX Michele L. Pearson, MD (Executive Secretary) Centers for Disease Control and Prevention Atlanta, GA Raymond Y.W. Chinn, MD Sharp Memorial Hospital San Diego, CA Alfred DeMaria, Jr, MD Massachusetts Department of Public Health Jamaica Plain, MA James T. Lee, MD, PhD University of Minnesota Minneapolis, MN William A. Rutala, PhD, MPH University of North Carolina Health Care System Chapel Hill, NC William E. Scheckler, MD University of Wisconsin Madison, WI Beth H. Stover, RN Kosair Children’s Hospital Louisville, KY Marjorie A. Underwood, RN, BSN CIC Mt. Diablo Medical Center Concord, CA This guideline discusses use of products by healthcare personnel in healthcare settings such as hospitals, ambulatory care and home care; the recommendations are not intended for consumer use of the products discussed. 2
  • Investigating Cell Type Specific Mechanisms Contributing to Acute Oral Toxicity

    Investigating Cell Type Specific Mechanisms Contributing to Acute Oral Toxicity

    Prieto et al.: Investigating cell type specific mechanisms contributing to acute oral toxicity Supplementary Data1 Tab. S1: Overview of collected information on specific target organ/system and general cytotoxicity for chemicals correctly assigned to the CLP acute oral toxicity category by the 3T3 NRU cytotoxicity assay General Nervous Cardiovascular GI Chemical Liver Lung Blood Kidney cytotoxicity system system system (±)-Propranolol hydrochloride x ax (4-ammonio-m-tolyl)ethyl(2- x x hydroxyethyl)ammonium sulphate 1,2,4-Trichlorobenzene x x 1,2-Dichlorobenzene x x 2,4,6- x x Tris(dimethylaminomethyl)phenol 2,4-Dichlorophenoxyacetic acid x x x 5,5-Diphenylhydantoin x x 5-Fluorouracil x x x x Acetophenone x Acetylsalicylic acid x x x x x x Acrolein x x Acrylamide x x x Ammonium chloride x ax ax Atropine sulfate monohydrate x x Benzaldehyde x x Cadmium (III) chloride x x x x x Caffeine x x x Chloroform x x ax x x x x Chloroquine bis(phosphate) x x Chlorpromazine x x x Codeine x x x x Colchicine x x x x Copper sulphate x x x Cupric sulfate pentahydrate x x Cyclosporin A x x x x Diazepam x Diphenhydramine hydrochloride x x Disopyramide x x Ethyl chloroacetate x x Ferrous sulphate x x x Glufosinate-ammonium x Glutethimide x ax x Hexachlorophene x x Lithium Carbonate x x x Lithium sulphate x x x Malathion x x Maleic acid x x Meprobamate x x Orphenadrine hydrochloride x x x x p-Benzoquinone x x x Phenol x x x x x Procainamide hydrochloride x x x Quinidine sulfate dehydrate x x x Resorcinol x x Rifampicin x x doi:10.14573/altex.1805181s2 ALTEX ##(#), SUPPLEMENTARY DATA 1 General Nervous Cardiovascular GI Chemical Liver Lung Blood Kidney cytotoxicity system system system Sodium Cyanate x x sodium oxalate x x x Sodium valproate x bx x x Thioridazine hydrochloride x x Valproic acid x x x x x GI: Gastrointestinal; CLP: Classification, labelling and packaging; NRU: Neutral Red Uptake; a Indirect effect: b chronic effect Tab.
  • 2019 Minnesota Chemicals of High Concern List

    2019 Minnesota Chemicals of High Concern List

    Minnesota Department of Health, Chemicals of High Concern List, 2019 Persistent, Bioaccumulative, Toxic (PBT) or very Persistent, very High Production CAS Bioaccumulative Use Example(s) and/or Volume (HPV) Number Chemical Name Health Endpoint(s) (vPvB) Source(s) Chemical Class Chemical1 Maine (CA Prop 65; IARC; IRIS; NTP Wood and textiles finishes, Cancer, Respiratory 11th ROC); WA Appen1; WA CHCC; disinfection, tissue 50-00-0 Formaldehyde x system, Eye irritant Minnesota HRV; Minnesota RAA preservative Gastrointestinal Minnesota HRL Contaminant 50-00-0 Formaldehyde (in water) system EU Category 1 Endocrine disruptor pesticide 50-29-3 DDT, technical, p,p'DDT Endocrine system Maine (CA Prop 65; IARC; IRIS; NTP PAH (chem-class) 11th ROC; OSPAR Chemicals of Concern; EuC Endocrine Disruptor Cancer, Endocrine Priority List; EPA Final PBT Rule for 50-32-8 Benzo(a)pyrene x x system TRI; EPA Priority PBT); Oregon P3 List; WA Appen1; Minnesota HRV WA Appen1; Minnesota HRL Dyes and diaminophenol mfg, wood preservation, 51-28-5 2,4-Dinitrophenol Eyes pesticide, pharmaceutical Maine (CA Prop 65; IARC; NTP 11th Preparation of amino resins, 51-79-6 Urethane (Ethyl carbamate) Cancer, Development ROC); WA Appen1 solubilizer, chemical intermediate Maine (CA Prop 65; IARC; IRIS; NTP Research; PAH (chem-class) 11th ROC; EPA Final PBT Rule for 53-70-3 Dibenzo(a,h)anthracene Cancer x TRI; WA PBT List; OSPAR Chemicals of Concern); WA Appen1; Oregon P3 List Maine (CA Prop 65; NTP 11th ROC); Research 53-96-3 2-Acetylaminofluorene Cancer WA Appen1 Maine (CA Prop 65; IARC; IRIS; NTP Lubricant, antioxidant, 55-18-5 N-Nitrosodiethylamine Cancer 11th ROC); WA Appen1 plastics stabilizer Maine (CA Prop 65; IRIS; NTP 11th Pesticide (EPA reg.